Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea.

NCT07018544 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT07018544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07018544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea.
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Enrolling by invitation
Start date
November 19, 2024
Completion date
February 28, 2027
Enrollment
840 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

obesity and overweight